Brief: Dermapharm 9M Adjusted EBITDA EUR 240.3 Million
Nov 14 (Reuters) - Dermapharm 9M EBITDA margin 26.3%. * 9M adjusted EBITDA margin 27% * 9M revenue EUR 890.1 million * 9M EBITDA EUR 234.1 million
Recent news on Dermapharm Holding SE
See all newsBrief: Dermapharm Confirms 2026 Forecast
Corrected: Germany's Dermapharm prelim H1 revenue rises, maintains outlook
Brief: Dermapharm Holding - Confirms Full-Year Guidance For 2026
Brief: Dermapharm Spokesperson - Dermapharm Is Engaged In A Constructive Dialogue With The Regulator
Refile: BUZZ-Dermapharm Holding slips after BaFin's audit